Bridged Six-Membered Ring Compounds for Calcium Channel Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel calcium channel blockers that can effectively target both T-type and L-type channels without the safety issues associated with existing compounds like mibefradil, such as CYP 3A4 drug interactions, ECG abnormalities, and adverse side effects.
Innovation Solution
Development of bridged six-membered ring compounds that act as potent T/L-type calcium channel blockers, specifically designed to address the safety concerns of previous agents by providing a more favorable pharmacological profile.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mibefradil is used as a T/L-type calcium channel blocker, then superior cardiovascular protection and renal protection are achieved, but CYP 3A4 drug interactions, ECG abnormalities, and adverse side effects occur
Solution Approach 1:
The patent extracts and eliminates the harmful CYP 3A4 interaction component from the calcium channel blocker molecule while preserving the beneficial T/L-type channel blocking activity. This is achieved through structural modification of the mibefradil scaffold to create compounds that do not interact with CYP 3A4 enzymes.
Solution Approach 2:
The patent modifies chemical parameters of the calcium channel blocker structure, specifically changing molecular geometry and functional groups to alter metabolic pathways. This transforms the compound's interaction profile with liver enzymes while maintaining its pharmacological activity on calcium channels.
2Reliability
If mibefradil is used as a T/L-type calcium channel blocker, then superior cardiovascular protection and renal protection are achieved, but ECG abnormalities and adverse side effects occur
Solution Approach 1:
The patent removes the side effect-generating components from the molecule while retaining the core calcium channel blocking activity. By modifying the molecular structure, the compound maintains its protective effects without generating ECG abnormalities or other adverse effects.
Solution Approach 2:
The patent transforms the molecular structure to convert potentially harmful metabolic interactions into beneficial pharmacokinetic profiles, where the compound achieves its therapeutic effect without causing the harmful side effects associated with mibefradil.
3Ease of operation
If L-type calcium channel blockers are used predominantly, then treatment of hypertension and angina is achieved, but inotropy, reflex tachycardia, vasoconstrictive hormone release, and peripheral edema occur
Solution Approach 1:
The patent creates a universal calcium channel blocker that acts on both T-type and L-type channels simultaneously. This multi-functional approach allows the compound to achieve therapeutic benefits through dual mechanisms while avoiding the compensatory reflex tachycardia that occurs with selective L-type blockers.
Solution Approach 2:
The patent merges the pharmacological actions of T-type and L-type calcium channel blocking into a single compound. By combining these activities, the drug achieves superior cardiovascular protection without the adverse effects associated with selective L-type channel blockade.
Data Source
AI summary
The invention relates to compounds of formula (I), wherein R1, R2, R1a, R2a, R3, R4, A, B, X, W and n are as defined in the description, and pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers.